Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2022-10-20
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 50710 NOK
Award criteria: Lowest price

Technical requirements: Voluntary ex-ante transparency notice - dexamethasone natrium phosphate eye drops for national preparedness reserves
The government has decided that two levels of medicine reserves are to be established in Norway. A decision has been made in project B180 preparedness reserves (National Reserves of Medicines), owned by Helse Vest RHF and managed by Sjukehusapoteka Vest HF, that a national reserve must be established for several selected medicines.
ATC code S01BA01, Dexamethasone natrium phosphate, Spersadex 1mg/ml eye drops 1000 pcs, max AIP = NOK 50,710
The government has decided that two levels of medicine reserves are to be established in Norway. A decision has been made in project B180 preparedness reserves (National Reserves of Medicines), owned by Helse Vest RHF and managed by Sjukehusapoteka Vest HF, that a national reserve must be established for several selected medicines.
ATC code S01BA01, Dexamethasone natrium phosphate, Spersadex 1mg/ml eye drops 1000 pcs, max AIP = NOK 50,710
Sykehusinnkjøp HF, medicines division (Sykehusinnkjøp), is procuring and obtaining tenders for health company financed medicines. Sykehusinnkjøp has been given a mandate to procure the medicine. Sykehusinnkjøp has previously published and held an open tender contest for pharmaceutical special preparations ("LIS 2201b Non-parenteral pharmaceutical special preparations). The contest included the mentioned medicine, as the tender documentation annex 3 - 'Price Sheet' requested tenders for the active ingredient (the medicine or reasonable alternatives).
Tenders were not received in the above-mentioned contest for the active ingredient in question (medicine or reasonable alternatives), and this part of the contest must therefore be marked as unsuccessful.
Sykehusinnkjøp has now examined which relevant medicines fulfil the regulatory requirements in Norway. If a medicine has a marketing licence in Norway, you cannot just procure an alternative medicine with a marketing licence in another country in the EU/EEA area. This is in the law on medicines, etc., Sections 8 and 10, sml. regulations on medicines chapter 2. This is further connected to Sykehusinnkjøp as a medicine intermediary having a right to its operations, c.f., the regulations on wholesaler operations with medicines, § 33a.
Based on this, Sykehusinnkjøp intends to procure Spersadex eye drops from Bluemont Ofta Trading for Helse Vest RHF.
Sykehusinnkjøp requests that any objections to this notice of intent are submitted and received by Sykehusinnkjøp before the end of the waiting period, which is set at 10 calendar days from the day after the notice of intent is published. If no objections are received, a contract will be signed after the waiting period has expired.
In the contest LIS 2201b non-parenteral medicines, no tenders were received for the active ingredient/medicine form (the medicine or reasonable alternatives), and this part of the contest must therefore be marked as unsuccessful.
The specialist group for the National Preparedness Reserves, B180, has decided that the medicine shall be kept in preparedness for the specialist health service in Norway. The value of the procurement is less than NOK 100,000.
Based on this, Sykehusinnkjøp intends to procure Spersadex eye drops from Bluemont Ofta Trading for Helse Vest RHF.


Winner: BLUMONT PHARMA LTD
Award value: 50710